Pancreatic Cancer Research

ResearcherThe Cancer Institute HospitalActive in the last 2 years

Yosuke Inoue

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5812-6608; OpenAlex author ID A5043441615. Sources: OpenAlex.

Their work

Papers
57 (first author 12, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
195
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 4 papers · 2021: 2 papers · 2022: 11 papers · 2023: 12 papers · 2024: 3 papers · 2025: 10 papers · 2026: 10 papers

Papers 50 of 57

  1. Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2026.1810↗
  2. Survival Impact After Resection for Postoperative Recurrence or Metastasis of Pancreatic Ductal Adenocarcinoma Analyzed Using a Time-Dependent Cox Regression M… Co-author DOI 10.1002/jhbp.70054↗
  3. Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy. Co-author DOI 10.1002/jhbp.70058↗
  4. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  5. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  6. Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. Co-author DOI 10.1038/s41416-025-03308-7↗
  7. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  8. Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on S… Co-author DOI 10.1097/sla.0000000000006638↗
  9. ASO Author Reflections: Beware the Collaterals: Vein Formation Signals Higher Surgical Risk in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18960-9↗
  10. ASO Visual Abstract: Surgical Challenges Associated with Collateral Veins Formation in Pancreatic Cancer with Vein Resection. Co-author DOI 10.1245/s10434-025-19046-2↗
  11. Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter… Co-author DOI 10.1002/ags3.70001↗
  12. Anatomical evaluation of the perinephric vein as a surgical landmark in minimally invasive distal pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s00464-025-12125-1↗
  13. Textbook oncologic outcome in pancreatic cancer surgery: Quality metric or prognostic marker? Co-author DOI 10.1016/j.pan.2025.10.002↗
  14. Exploring the role of CA 19-9 dynamics in pancreatic cancer multidisciplinary treatment: Proposal of the PANC classification. Co-author DOI 10.1016/j.surg.2025.109783↗
  15. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  16. Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal comparative study. Co-author DOI 10.1093/bjsopen/zraf026↗
  17. Long-term Outcomes Following Resection of Adenocarcinoma Arising from Intraductal Papillary Mucinous Neoplasm (A-IPMN) Versus Pancreatic Ductal Adenocarcinoma … Co-author DOI 10.1097/sla.0000000000006272↗
  18. Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overall and by Adjuvant Chemotherapy Regimens. Co-author DOI 10.1245/s10434-025-17289-7↗
  19. Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy. Co-author DOI 10.1245/s10434-025-17407-5↗
  20. ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicator for Neoadjuvant Therapy. Co-author DOI 10.1245/s10434-025-17458-8↗
  21. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  22. Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemoth… Co-author DOI 10.1002/jhbp.12066↗
  23. Unique Biology of Pancreatic Ductal Adenocarcinoma Accompanied by Rapidly Impaired Diabetes: A Favorable Long-Term Survival Following Curative Resection. Co-author DOI 10.1245/s10434-023-14408-0↗
  24. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression. Co-author DOI 10.1002/cjp2.323↗
  25. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Soc… Co-author DOI 10.1002/cncr.34580↗
  26. Outcomes of pancreatic cancer with liver oligometastasis. Co-author DOI 10.1002/jhbp.1184↗
  27. Feasibility of laparoscopic radical antegrade modular pancreatosplenectomy (RAMPS) as a standard treatment for distal resectable pancreatic cancer. Co-author DOI 10.1007/s00423-023-02942-0↗
  28. New approach of circumferential lymph node dissection around the superior mesenteric artery for pancreatic cancer during pancreaticoduodenectomy (with video). First author DOI 10.1007/s00423-023-03159-x↗
  29. Radical antegrade modular pancreatosplenectomy enhances local control of the disease in patients with left-sided pancreatic cancer. Co-author DOI 10.1016/j.hpb.2022.08.004↗
  30. Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with e… First author DOI 10.1016/j.hpb.2022.09.012↗
  31. Intraoperative paraaortic lymph node sampling during resection for pancreatic cancer: evolving role in the modern chemotherapy era. Co-author DOI 10.1016/j.hpb.2023.05.366↗
  32. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Co-author DOI 10.1016/j.pan.2023.06.005↗
  33. Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005395↗
  34. Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery. First author DOI 10.1245/s10434-023-13534-z↗
  35. Impact of sarcopenia on S1 adjuvant chemotherapy and prognosis in pancreatic cancer patients. First author DOI 10.5582/bst.2023.01209↗
  36. New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). Co-author DOI 10.1002/jhbp.1049↗
  37. Long-Term Outcome of Patients with Postoperative Refractory Diarrhea After Tailored Nerve Plexus Dissection Around the Major Visceral Arteries During Pancreato… Co-author DOI 10.1007/s00268-022-06457-5↗
  38. Early-onset pancreatic cancer: Clinical characteristics and survival outcomes. Co-author DOI 10.1016/j.pan.2022.04.003↗
  39. KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. Co-author DOI 10.1111/cas.15398↗
  40. Diabetogenic liver metastasis from pancreatic cancer: a case report. Co-author DOI 10.1186/s40792-022-01582-8↗
  41. Impact of Tumor Size on the Outcomes of Patients with Resectable Distal Pancreatic Cancer: Lessons Learned from a Series of 158 Radical Resections. Co-author DOI 10.1245/s10434-021-10560-7↗
  42. ASO Author Reflections: Size Matters in Distal Pancreatic Cancer: Predictor for Failure of Upfront Resection for Radiologically Resectable Disease. Co-author DOI 10.1245/s10434-021-10686-8↗
  43. Laparoscopic Radical Antegrade Modular Pancreatosplenectomy with Anterocranial Splenic Artery-First Approach for Left-Sided Resectable Pancreatic Cancer (with … First author DOI 10.1245/s10434-022-11382-x↗
  44. Prediction of Recurrence Pattern of Pancreatic Cancer Post-Pancreatic Surgery Using Histology-Based Supervised Machine Learning Algorithms: A Single-Center Ret… Co-author DOI 10.1245/s10434-022-11471-x↗
  45. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOL… First author DOI 10.1245/s10434-022-11503-6↗
  46. ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcit… First author DOI 10.1245/s10434-022-11621-1↗
  47. High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment. First author DOI 10.1016/j.pan.2020.11.026↗
  48. Staging laparoscopy for pancreatic cancer using intraoperative ultrasonography and fluorescence imaging: the SLING trial. First author DOI 10.1093/bjs/znaa111↗
  49. Regional pancreatoduodenectomy versus standard pancreatoduodenectomy with portal vein resection for pancreatic ductal adenocarcinoma with portal vein invasion. Co-author DOI 10.1002/bjs5.50268↗
  50. Radiologically occult metastatic pancreatic cancer: how can we avoid unbeneficial resection? First author DOI 10.1007/s00423-019-01846-2↗

Closest collaborators

The 25 strongest of 195 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Atsushi Oba · 35 shared papers, 2019–2026 · strength 6.14
  2. Yu Takahashi · 37 shared papers, 2017–2026 · strength 5.91
  3. Hiromichi Ito · 29 shared papers, 2017–2025 · strength 4.78
  4. Yoshihiro Ono · 24 shared papers, 2019–2026 · strength 3.94
  5. Naoki Sasahira · 18 shared papers, 2020–2026 · strength 3.10
  6. Akio Saiura · 21 shared papers, 2018–2024 · strength 2.99
  7. Masato Ozaka · 13 shared papers, 2020–2026 · strength 2.35
  8. Takashi Sasaki · 11 shared papers, 2020–2026 · strength 1.84
  9. Takafumi Mie · 9 shared papers, 2020–2026 · strength 1.69
  10. Tsuyoshi Takeda · 10 shared papers, 2020–2026 · strength 1.66
  11. Aya Maekawa · 8 shared papers, 2023–2026 · strength 1.61
  12. Manabu Takamatsu · 9 shared papers, 2022–2026 · strength 1.54
  13. Yoshihiro Ono · 7 shared papers, 2022–2025 · strength 1.36
  14. Sohei Satoi · 7 shared papers, 2022–2026 · strength 1.13
  15. Kojiro Omiya · 5 shared papers, 2023–2026 · strength 1.04
  16. Tomotaka Kato · 5 shared papers, 2022–2026 · strength 0.89
  17. Michiaki Unno · 5 shared papers, 2023–2026 · strength 0.89
  18. Daisuke Hashimoto · 5 shared papers, 2023–2026 · strength 0.88
  19. Tatsunori Suzuki · 5 shared papers, 2022–2026 · strength 0.81
  20. Yousuke Nakai · 5 shared papers, 2022–2026 · strength 0.81
  21. Daisuke Ban · 4 shared papers, 2025–2026 · strength 0.81
  22. Masamichi Mizuma · 4 shared papers, 2025–2026 · strength 0.76
  23. Tatsunori Miyata · 3 shared papers, 2026 · strength 0.73
  24. Ippei Matsumoto · 4 shared papers, 2023–2026 · strength 0.64
  25. Kiyoshi Hasegawa · 4 shared papers, 2022–2026 · strength 0.63

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.